| 刘寿贵,林舜国.白蛋白结合型紫杉醇治疗紫杉类耐药转移性乳腺癌47例[J].肿瘤学杂志,2018,24(7):692-695. |
| 白蛋白结合型紫杉醇治疗紫杉类耐药转移性乳腺癌47例 |
| Albumin-Bound Paclitaxel for 47 Patients with Taxane-Resistant Metastatic Breast Cancer |
| 投稿时间：2017-06-23 |
| DOI：10.11735/j.issn.1671-170X.2018.07.B008 |
|
 |
| 中文关键词: 白蛋白结合型紫杉醇 转移性乳腺癌 紫杉醇 耐药 |
| 英文关键词:albumin-bound paclitaxel metastatic breast cancer taxane resistant |
| 基金项目: |
|
| 摘要点击次数: 2219 |
| 全文下载次数: 974 |
| 中文摘要: |
| 摘 要：［目的］ 探讨白蛋白结合型紫杉醇在传统紫杉类治疗失败的转移性乳腺癌中的近期疗效及安全性。［方法］ 筛选47例传统紫杉类（紫杉醇、多西紫杉醇）治疗失败转移性乳腺癌患者，其中31例行白蛋白结合型紫杉醇单药化疗，12例行白蛋白结合型紫杉醇联合卡培他滨化疗，4例行白蛋白结合型紫杉醇联合曲妥珠单抗方案化疗，观察患者的近期疗效和不良反应。［结果］ 47例患者治疗有效率为14.89%，临床获益率为57.45%，中位PFS 3.9个月。患者主要不良反应为中性粒细胞减少及感觉神经毒性。［结论］ 白蛋白结合型紫杉醇对紫杉类治疗失败的转移性乳腺癌仍具有良好的疗效，不良反应可耐受。 |
| 英文摘要: |
| Abstract：［Objective］ To explore the antitumor the short-term curative effect and safety of albumin-bound paclitaxel in patients with metastatic or recurrent breast cancer whose diseases progressed despite conventional taxane therapy. ［Methods］ Forty-seven patients with recurrent or metastatic breast cancer with taxane-resistant(paclitaxel or docetaxel ) were enrolled. The 31 patients received single-agent albumin-bound paclitaxel，12 patients with combination of capecitabine and albumin-bound paclitaxel therapy，4 patients with combination of trastuzumab and albumin-bound paclitaxel. All of the patients were evaluated for short term efficacy and adverse events. ［Results］ Of 47 patients，the overall response rate and clinical benefit rates was 14.89% and 57.45%，respectively. The median progression free survival was 3.9 months. The predominant toxicities were neutropenia and sensory neuropathy. ［Conclusion］ Albumin-bound paclitaxel treatment of advanced breast cancer well tolerated has a favorable therapeutic efficacy after the failure of taxane therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |